CD8A and neoplasm: Blocking IRE1α function in tumor-bearing mice using a highly specific kinase-based IRE1α inhibitor upregulated MHC-I levels on DCs, enhanced tumor recruitment and activation of CD8+ T cells, and cooperated with anti–programmed death ligand 1 (PD-L1) immune-checkpoint disruption to cause tumor regression.